Your search for esrd returned 70 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for esrd returned 70 results

Sort Results:

Relevant Recent
News

Vancomycin Overprescribed in Bloodstream MSSA Infections

In U.S. dialysis centers treating end-stage renal (ESRD) patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, vancomycin is overprescribed, despite evidence of lower rates of hospitalization and death in cefazolin-treated patients.
News

Fenofibrate Found Safe in Diabetes With Renal Impairment

Long-term daily use of fenofibrate is beneficial for patients with type 2 diabetes and moderate renal impairment and is not associated with an increase in drug-related safety concerns compared with those with mild renal impairment.
Drugs in the Pipeline

Phase 3 Study of Zerenex for Hyperphosphatemia in ESRD

Keryx Biopharmaceuticals announced positive final data from its Phase 3 study of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis.
American College of Cardiology 2011

Lipid Management in Special Populations

Statins are the most widely prescribed agents in the world. While muscle-related adverse effects associated with statins are well known, accurately quantifying their incidence to guide clinicians with respect to lipid management can be difficult, said Richard H. Karas, MD, PhD, Tufts Medical Center, Boston, at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.
News

Onglyza labeling updated to include new clinical trial data

The labeling for Onglyza (saxagliptin; Bristol-Myers Squibb) has been updated to include data from two clinical trials: a study of Onglyza in patients with moderate to severe renal impairment or end-stage renal disease (ESRD) and a second comparator study of Onglyza + metformin versus glipizide + metformin.